Core Viewpoint - Luant Pharmaceutical (600789.SH) has received approval from the Shanghai Stock Exchange for its application to issue shares to specific investors, pending final approval from the China Securities Regulatory Commission (CSRC) [1] Fundraising Details - The total amount to be raised from the issuance is not exceeding 120 million yuan, which will be allocated to projects including high-end formulation intelligent manufacturing workshop, bio-pesticide base construction, new drug research and development, and working capital [1][2] - The total investment for the projects is approximately 128.42 million yuan, with specific allocations as follows: - High-end formulation intelligent manufacturing workshop: 44.24 million yuan - Bio-pesticide base construction: 43.22 million yuan - New drug research and development: 20.97 million yuan - Working capital: 20 million yuan [2] Issuance Participants - The issuance will involve no more than 35 qualified investors, including Hualu Group, which plans to subscribe for 23.81% of the shares issued, amounting to no more than 64,201,417 shares [3] - Other potential investors include securities investment fund management companies, securities firms, financial companies, asset management companies, insurance institutions, trust companies, and qualified foreign institutional investors [2] Shareholding Structure - As of September 30, 2024, the total share capital of the company is 898,669,632 shares, with Hualu Group holding 20.69% and Hualu Investment holding 3.13% [5] - Post-issuance, Hualu Group's shareholding will remain unchanged, ensuring that the control of the company does not change [5] Regulatory Compliance - The issuance is subject to compliance with relevant laws and regulations, and the company will fulfill its information disclosure obligations as required [1][4]

Group 1 - The company held its second board meeting of the seventh session on August 18, 2025, with all nine directors present, and the meeting was deemed legally valid [2][3]. - The board approved a proposal to reduce the total amount of funds raised through a simplified procedure for issuing shares to specific targets from 175.29 million yuan to 125.29 million yuan [3][7]. - The number of shares to be issued was adjusted from 12,785,769 shares to 9,138,795 shares, which does not exceed 30% of the company's total share capital before the issuance [4][6]. Group 2 - The adjusted total amount of funds to be raised is 125.29 million yuan, which is still within the limit of 300 million yuan and does not exceed 20% of the company's net assets at the end of the previous year [7][26]. - The net proceeds from the fundraising will be invested in projects related to vaccine research and production, with the company allowed to adjust the investment sequence and amounts based on actual needs [6][34]. - The board also approved a feasibility analysis report regarding the use of funds raised through the issuance of shares, confirming that the funds will be used for projects in the field of technological innovation [12][18]. Group 3 - The company has committed to measures to mitigate the dilution of immediate returns resulting from the share issuance, including maintaining stable business growth and accelerating project investment [40][46]. - The company has a strong talent reserve, with a stable management team and ongoing recruitment efforts to enhance its human resources [36]. - The company has established a comprehensive technical reserve, focusing on vaccine research and development, and has formed partnerships with academic institutions to enhance its innovation capabilities [37][38]. Group 4 - The company plans to strengthen its fundraising management to ensure compliance and effective use of the raised funds, with regular checks and disclosures on fund usage [42]. - The company aims to accelerate the construction of fundraising investment projects to enhance its competitiveness and sustainable development [43]. - The company has developed a profit distribution policy to ensure stable returns for investors, particularly small and medium shareholders [44][45].

证券代码：688319 证券简称：欧林生物 公告编号：2025-035 成都欧林生物科技股份有限公司 第七届董事会第二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 成都欧林生物科技股份有限公司（以下简称"公司"）于 2025 年 8 月 18 日以现场及通讯方式在公司会议室召开第七届董事会第二次会议（以下简称"本 次会议"）。经全体董事同意，本次会议豁免通知时限要求。本次会议由公司董 事长樊绍文先生召集并主持，应出席董事 9 人，实际出席会议董事 9 人。本次会 议的通知、召开及审议程序符合《中华人民共和国公司法》《上海证券交易所科 创板股票上市规则》等法律法规、规范性文件及《成都欧林生物科技股份有限公 司章程》（以下简称"《公司章程》"）的有关规定，会议决议合法有效。 二、董事会会议审议情况 经与会董事审议，本次会议通过如下议案： （一）审议通过了《关于调减公司以简易程序向特定对象发行股票募集资 金总额暨调整发行方案的议案》 根据《中华人民共和国证券法》《上市公司证券发行注册管理 ...

成都欧林生物科技股份有限公司（以下简称"公司"）于 2024 年 10 月 29 日召开第六届董事会第十七次会议审议通过了《关于公司以简易程序向特定对象 发行股票预案的议案》等相关议案，于 2025 年 6 月 25 日召开第六届董事会第二 十一次会议通过了《关于公司以简易程序向特定对象发行股票竞价结果的议案》 关于以简易程序向特定对象发行人民币普通股 （A 股）股票预案修订说明的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688319 证券简称：欧林生物 公告编号：2025-037 成都欧林生物科技股份有限公司 《关于公司与特定对象签署附生效条件的股份认购协议的议案》等相关议案。 简易程序向特定对象发行 A 股股票预案（二次修订稿）的议案》《关于与特定 对象重新签署附生效条件的股份认购协议的议案》等相关议案。 导致公司控制权发生 4、更新了本次发行已履行决策程序的情况 变化 八、本次向特定对 根据公司董事会审议通过的向特定对象发行股票预案，本次发行募集资金总 额为 12,529.29 万元，符合以简易 ...

Core Viewpoint - The company is set to issue A-shares to specific investors in 2025, with the supervisory board confirming compliance with relevant laws and regulations, ensuring the feasibility and legality of the issuance [2][5]. Group 1: Compliance and Feasibility - The company meets the qualifications and conditions for issuing shares to specific investors as per the Company Law, Securities Law, and relevant regulations [2]. - The proposed stock issuance plan, feasibility analysis, and related resolutions are in accordance with legal requirements, ensuring no significant legal or policy obstacles exist [2][3]. - The pricing method for the issuance is fair and does not harm the interests of the company or minority shareholders [2]. Group 2: Fund Utilization and Financial Health - The funds raised from this issuance will be used in a manner that aligns with the company's actual situation, enhancing capital strength, optimizing asset structure, and improving cash flow [2][3]. - The issuance is expected to strengthen the company's competitive advantage and align with long-term development goals and shareholder interests [2]. Group 3: Shareholder Returns and Protection - The company has analyzed the impact of the stock issuance on immediate returns and proposed specific measures to mitigate any dilution effects, with commitments from directors and senior management to protect shareholder interests [3]. - The company's dividend return plan for 2025-2027 is designed to provide stable returns to investors while ensuring sustainable development [3]. Group 4: Authorization and Approval Process - The request for shareholder meeting authorization for the board of directors to handle the issuance is compliant with legal regulations, facilitating an efficient process [3][4]. - The preparation and review procedures for the stock issuance documents adhere to all legal and internal management requirements, pending approval from the shareholders and regulatory bodies [4].

一、本次向特定对象发行股票的发行价格和发行数量的调整依据 本次向特定对象发行股票的相关议案已经公司 2024 年 10 月 9 日召开的第五 届董事会第三次会议、2025 年 1 月 16 日召开的 2025 年第一次临时股东大会审 议通过。根据《青岛达能环保设备股份有限公司 2024 年度向特定对象发行 A 股 股票预案》，若公司股票在定价基准日至发行日期间发生派息、送红股、资本公 积转增股本等除权除息事项，将对本次发行价格作相应调整。本次发行方案中关 于发行价格及发行数量的具体条款如下： （一）定价基准日、发行价格及定价原则 公司本次向特定对象发行股票的定价基准日为公司第五届董事会第三次会 议决议公告日，即 2024 年 10 月 10 日。 本次向特定对象发行股票定价基准日前 20 个交易日公司股票交易均价为 定价基准日前 20 个交易日股票交易均价的 80%（定价基准日前 20 个交易日股票 交易均价=定价基准日前 20 个交易日股票交易总额/定价基准日前 20 个交易日股 票交易总量）。 证券代码：688501 证券简称：青达环保 公告编号：2025-037 青岛达能环保设备股份有限公司 关于 20 ...

Core Viewpoint - The legal opinion letter from Beijing Jiayuan Law Firm confirms that Fengshen Tire Co., Ltd. is eligible to issue A-shares to specific investors in compliance with relevant laws and regulations [2][5][21]. Group 1: Issuance Authorization and Approval - The issuance has been authorized and approved according to the requirements of the Company Law and the company's articles of association, ensuring that the relevant resolutions are legal and effective [7][21]. - The issuance is directed towards specific investors and does not involve public solicitation, aligning with the Securities Law [8][12]. Group 2: Issuance Conditions - The issuance meets the conditions set forth in the Company Law, including that each share has the same rights and the issuance price is not lower than the par value [7][8]. - The issuance complies with the Registration Management Measures, with no changes in the use of previously raised funds and no significant issues in the financial reports audited by Yongcheng [9][10]. Group 3: Company Structure and Control - The major shareholder, China National Chemical Corporation, holds 57.50% of the shares, and the actual controller is the State-owned Assets Supervision and Administration Commission, ensuring that the control of the company remains unchanged post-issuance [10][16]. - The company has not engaged in significant illegal activities that would harm the interests of investors or the public in the last three years [10][14]. Group 4: Fund Utilization - The funds raised will be used for the high-performance giant engineering radial tire expansion project, which aligns with the company's main business and complies with national industrial policies [11][20]. - The project has received necessary approvals from relevant authorities, ensuring compliance with environmental and land management laws [11][20]. Group 5: Legal Compliance and Risk Management - The company has confirmed that there are no significant legal risks or pending litigation that could adversely affect the issuance [20][21]. - The legal opinion emphasizes that the issuance will not lead to any significant adverse effects on the company's operations or its independence [20][21].

Group 1 - The company, Xinjiang L新能源股份有限公司, is in the process of applying for a specific stock issuance, which requires approval from the Shenzhen Stock Exchange and registration consent from the China Securities Regulatory Commission [1][3] - The company has updated and revised its application documents, including the "Audit Inquiry Letter," "Fundraising Prospectus," and "Listing Sponsorship Letter," in accordance with relevant regulations [1] - The company emphasizes that the final approval and registration timeline remains uncertain, and it will continue to fulfill its information disclosure obligations as required by law [1][2]

Meeting Overview - The 7th meeting of the 9th Board of Directors of Xinjiang International Industry Co., Ltd. was held on August 14, 2025, with all 7 directors present [1] Resolutions Passed - The board approved the extension of the validity period for the resolution on issuing shares to specific targets, with 5 votes in favor and 2 abstentions [1] - The board approved the proposal to extend the authorization for the board to handle matters related to issuing shares to specific targets, with unanimous support of 7 votes [2] - The board approved amendments to the Articles of Association to enhance corporate governance and compliance with relevant laws, with unanimous support of 7 votes [2] - The board approved amendments to the Rules of Procedure for Shareholders' Meetings, with unanimous support of 7 votes [3] - The board approved amendments to the Rules of Procedure for Board Meetings, with unanimous support of 7 votes [3] - The board approved amendments to the Implementation Rules for Special Committees of the Board, with unanimous support of 7 votes [3] - The board approved amendments to the Insider Information Knowledge Person Registration Management System, with unanimous support of 7 votes [4] - The board approved amendments to the Information Disclosure Management System, with unanimous support of 7 votes [4] - The board approved amendments to the Major Information Internal Reporting System, with unanimous support of 7 votes [5] - The board approved amendments to the Internal Audit System, with unanimous support of 7 votes [5] - The board approved the establishment of a Director Departure Management System, with unanimous support of 7 votes [5] - The board approved the proposal to hold the second temporary shareholders' meeting of 2025, with unanimous support of 7 votes [5] Documentation - The resolutions from the 7th meeting of the 9th Board of Directors and the independent directors' special meeting resolutions are available for review [6]

Meeting and Attendance - The seventh meeting of the ninth Supervisory Board of Xinjiang International Industry Co., Ltd. was held on August 14, 2025, combining in-person and communication methods, with all five supervisors present [1][2] Resolutions Passed - The Supervisory Board approved the proposal to extend the validity period of the resolution for issuing shares to specific objects, with a unanimous vote of 5 in favor [1] - The proposal to extend the authorization for the Board of Directors to handle matters related to the issuance of shares to specific objects was also approved, again with a unanimous vote of 5 in favor [1] - The proposal to amend the company's Articles of Association was approved to enhance corporate governance and promote standardized operations, with a unanimous vote of 5 in favor [2]